

July 26, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our earlier letter dated 30th May, 2025 on the inspection conducted by USFDA for our API Manufacturing facility at Z-103/I, SEZ, Phase II, District Bharuch, Dahej - 392 130, Gujarat from 26th May to 30th May, 2025. In furtherance to the aforementioned intimation, this is to inform you that the USFDA has issued an Establishment Inspection Report (“EIR”) with a No Action Indicated (“NAI”) classification for the said manufacturing facility.

Please take the information on your records.

Thanking You,

Your Sincerely,

For Alivus Life Sciences Limited

(formerly known as Glenmark Life Sciences Limited)

Rudalf Corriea

Company Secretary & Compliance officer

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com

